Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03829436
Title TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tempest Therapeutics
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of California - San Francisco San Francisco California 94158 United States Details
Miami Cancer Institute Miami Florida 33176 United States Details
Johns Hopkins University Baltimore Maryland 21287 United States Details
University of Michigan Rogel Cancer Center Ann Arbor Michigan 48109 United States Details
Columbia University Medical Center New York New York 10024 United States Details
Carolina BioOncology Institute Huntersville North Carolina 28078 United States Details
Stephenson Cancer Center Oklahoma City Oklahoma 73104 United States Details
University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania 19104 United States Details
Thomas Jefferson University Hospital Philadelphia Pennsylvania 19107 United States Details
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15213 United States Details
Sarah Cannon Research Institute - TN Nashville Tennessee 37203 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field